Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. announced that it has received $93.660000 million in funding from Yingke Innovation Asset Management Co., Ltd., Hosencare Investment Management Shanghai Ltd., Beijing Lanpu Capital Management Co.,Ltd., Jolmo Investment Management Co., Ltd., CITIC Securities Company Limited, GP Capital Co., Ltd and another investor.
Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd. announced that it has received $93,660,000 in funding led by CITIC Securities Company Limited and CITIC Med Funds. on June 4, 2021. The transaction included participation from Yingke Innovation Asset Management Co., Ltd., Hosencare Investment Management (Shanghai) Ltd., Beijing Lanpu Capital Management Co.,Ltd., Jolmo Investment Management Co., Ltd., and GP Capital Co., Ltd.